



Medi-Cal Rx

# Update to CCS Service Authorization Requests

March 4, 2022

Effective immediately, Medi-Cal Rx has implemented the following policy updates.

Medi-Cal Rx has identified claims denying for California Children's Services (CCS) beneficiaries when a previously approved product-specific Prior Authorization (PA), such as a historic Service Authorization Request (SAR), has expired.

Historically, a new PA would be required to allow the claim to pay for the excluded product. Medi-Cal Rx recognizes that this is causing disruption for CCS beneficiaries and has implemented the following short-term and long-term solutions.

## Short-Term Solution

Medi-Cal Rx will be extending the end date of historic product National Drug Code (NDC)-specific PAs that would have expired during the 180-day transition period to 06/30/2022. This will allow the historic SAR to be used through the 180-day transition period. This action is only for excluded products that have special considerations for CCS, Genetically Handicapped Persons Program (GHPP), and Early Periodic Screening, Diagnosis, and Treatment (EPSDT) beneficiaries.

Medi-Cal Rx will continue to evaluate and research CCS claims and PAs to ensure that they are processing appropriately.

## Long-Term Solution

Prime Therapeutics State Government Solutions LLC (Prime) has maintained a 24-hour PA turnaround time since 02/11/2022. In addition, Prime intends to add specialty clinical liaisons who can assist in resolving CCS PA and claim issues.